Essential Fatty Acid Deficiency in Cystic Fibrosis Disease Progression: Role of Genotype and Sex

Adequate intake of nutrients such as essential fatty acids (EFA) are critical in cystic fibrosis (CF). The clinical course of deterioration of lung function in people with CF has been shown to relate to nutrition. Independent of the higher energy consumption and malabsorption due to pancreatic insufficiency, EFA deficiency is closely associated with the risk of pulmonary infection, the most significant pathology in CF. This review will focus on the EFA deficiency identified in people with CF, as well as the limited progress made in deciphering the exact metabolic pathways that are dysfunctional in CF. Specifically, people with CF are deficient in linoleic acid, an omega 6 fatty acid, and the ratio of arachidonic acid (omega 6 metabolite) and docosahexaenoic acid (omega 3 metabolite) is increased. Analysis of the molecular pathways in bronchial cells has identified changes in the enzymes that metabolise EFA. However, fatty acid metabolism primarily occurs in the liver, with EFA metabolism in CF liver not yet investigated, indicating that further research is required. Despite limited understanding in this area, it is well known that adequate EFA concentrations are critical to normal membrane structure and function, and thus are important to consider in disease processes. Novel insights into the relationship between CF genotype and EFA phenotype will be discussed, in addition to sex differences in EFA concentrations in people with CF. Collectively, investigating the specific effects of genotype and sex on fatty acid metabolism may provide support for the management of people with CF via personalised genotype- and sex-specific nutritional therapies.

[1]  B. Strandvik Nutrition in Cystic Fibrosis—Some Notes on the Fat Recommendations , 2022, Nutrients.

[2]  E. Tizzano,et al.  Inflammation in cystic fibrosis patients: study of the eicosanoid pathway and severity correlations , 2021, ACM International Conference on Computing Frontiers.

[3]  C. Mingora,et al.  Pulmonary Complications in Cystic Fibrosis: past, present and future. , 2021, Chest.

[4]  B. Wielgomas,et al.  DeltaF508 CFTR Hetero- and Homozygous Paediatric Patients with Cystic Fibrosis Do Not Differ with Regard to Nutritional Status , 2021, Nutrients.

[5]  I. Doull,et al.  Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn? , 2021, Archives of Disease in Childhood.

[6]  J. Soriano,et al.  Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial. , 2020, Prostaglandins, leukotrienes, and essential fatty acids.

[7]  L. Agellon,et al.  Distinct Alteration of Gene Expression Programs in the Small Intestine of Male and Female Mice in Response to Ablation of Intestinal Fabp Genes , 2020, Genes.

[8]  A. McAinch,et al.  Maternal High Linoleic Acid Alters Placental Fatty Acid Composition , 2020, Nutrients.

[9]  B. Strandvik,et al.  Abnormal n-6 fatty acid metabolism in cystic fibrosis contributes to pulmonary symptoms. , 2020, Prostaglandins, leukotrienes, and essential fatty acids.

[10]  C. Farinha,et al.  The bidirectional relationship between CFTR and lipids , 2020, Communications Biology.

[11]  H. Watson,et al.  Omega-3 fatty acid supplementation for cystic fibrosis. , 2020, The Cochrane database of systematic reviews.

[12]  C. Knoop,et al.  Influence of lung transplantation on the essential fatty acid profile in cystic fibrosis. , 2020, Prostaglandins, leukotrienes, and essential fatty acids.

[13]  B. Harvey,et al.  Sexual dimorphism in the microbiology of the CF ‘Gender Gap’: Estrogen modulation of Pseudomonas aeruginosa virulence , 2019, Steroids.

[14]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[15]  L. Wood,et al.  Dietary Fatty Acids Amplify Inflammatory Responses to Infection through p38 MAPK Signaling , 2019, American journal of respiratory cell and molecular biology.

[16]  D. Nichols,et al.  Inflammation in cystic fibrosis: An update , 2018, Pediatric pulmonology.

[17]  F. Enjalbert,et al.  Enzymatic Study of Linoleic and Alpha-Linolenic Acids Biohydrogenation by Chloramphenicol-Treated Mixed Rumen Bacterial Species , 2018, Front. Microbiol..

[18]  M. Alves-Bezerra,et al.  Triglyceride Metabolism in the Liver. , 2017, Comprehensive Physiology.

[19]  P. Sly,et al.  Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It? , 2017, American journal of respiratory and critical care medicine.

[20]  J. Moczko,et al.  Determinants of Serum Glycerophospholipid Fatty Acids in Cystic Fibrosis , 2017, International journal of molecular sciences.

[21]  Zeynep Madak-Erdogan,et al.  Estrogen and Microbiota Crosstalk: Should We Pay Attention? , 2016, Trends in Endocrinology & Metabolism.

[22]  Miquéias Lopes-Pacheco,et al.  CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis , 2016, Front. Pharmacol..

[23]  C. Kelly,et al.  Islet-intrinsic effects of CFTR mutation , 2016, Diabetologia.

[24]  O. Umunakwe,et al.  Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase , 2014, Journal of Lipid Research.

[25]  D. Cassiman,et al.  Lung transplantation in cystic fibrosis normalizes essential fatty acid profiles. , 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[26]  Tamás Decsi,et al.  Gender Differences in the Long-Chain Polyunsaturated Fatty Acid Status: Systematic Review of 51 Publications , 2013, Annals of Nutrition and Metabolism.

[27]  N. McElvaney,et al.  Immune, inflammatory and infectious consequences of estrogen in women with cystic fibrosis , 2012, Expert review of respiratory medicine.

[28]  B. Strandvik,et al.  Relation Between Dietary Fat Intake Type and Serum Fatty Acid Status in Children With Cystic Fibrosis , 2012, Journal of pediatric gastroenterology and nutrition.

[29]  Matthias Griese,et al.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[30]  M. Laposata,et al.  Increased Δ5- and Δ6-desaturase, cyclooxygenase-2, and lipoxygenase-5 expression and activity are associated with fatty acid and eicosanoid changes in cystic fibrosis. , 2011, Biochimica et biophysica acta.

[31]  P. Sly,et al.  Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis , 2011, Thorax.

[32]  L. Touqui,et al.  Critical role of cytosolic phospholipase A2&agr; in bronchial mucus hypersecretion in CFTR-deficient mice , 2010, European Respiratory Journal.

[33]  M. Paluch,et al.  The linoleic acid influence on molecular interactions in the model of biological membrane. , 2009, Colloids and surfaces. B, Biointerfaces.

[34]  P. Lebecque,et al.  Influence of pancreatic status and sex on polyunsaturated fatty acid profiles in cystic fibrosis. , 2008, Clinical chemistry.

[35]  L. Badimón,et al.  Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. , 2007, Current pharmaceutical design.

[36]  E. Robberecht,et al.  Serum Zinc Concentrations in Cystic Fibrosis Patients Aged Above 4 Years: A Cross-sectional Evaluation , 2007, Biological Trace Element Research.

[37]  J. Mullol,et al.  Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis , 2006, Thorax.

[38]  John R. Riordan,et al.  Misassembled mutant ΔF508 CFTR in the distal secretory pathway alters cellular lipid trafficking , 2006, Journal of Cell Science.

[39]  A. J. Hulbert,et al.  Dietary fats and membrane function: implications for metabolism and disease , 2005, Biological reviews of the Cambridge Philosophical Society.

[40]  H. Verkade,et al.  No indications for altered essential fatty acid metabolism in two murine models for cystic fibrosis Published, JLR Papers in Press, October 1, 2004. DOI 10.1194/jlr.M400238-JLR200 , 2004, Journal of Lipid Research.

[41]  M. Regan,et al.  Association of cystic fibrosis with abnormalities in fatty acid metabolism. , 2004, The New England journal of medicine.

[42]  Ying Sun,et al.  Targeted Deletion of Fatty Acid Transport Protein-4 Results in Early Embryonic Lethality* , 2003, Journal of Biological Chemistry.

[43]  A. Simopoulos,et al.  The importance of the ratio of omega-6/omega-3 essential fatty acids. , 2002, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[44]  B. Strandvik,et al.  Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. , 2001, The Journal of pediatrics.

[45]  S. Freedman,et al.  A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  H. Verkade,et al.  The mechanisms of fat malabsorption in cystic fibrosis patients. , 1999, Nutrition.

[47]  M. Rosenfeld,et al.  Gender gap in cystic fibrosis mortality. , 1997, American journal of epidemiology.

[48]  B. Kerem,et al.  Genotype‐phenotype correlations in cystic fibrosis , 1996, Pediatric pulmonology.

[49]  W. Warwick,et al.  Serum fatty acid profiles in cystic fibrosis patients and their parents , 1994, Lipids.

[50]  N. Brown,et al.  The chloride channel blocker anthracene 9-carboxylate inhibits fatty acid incorporation into phospholipid in cultured human airway epithelial cells. , 1992, The Biochemical journal.

[51]  R. Kane,et al.  Energy and respiratory metabolism in cystic fibrosis: the influence of carbohydrate content of nutritional supplements. , 1991, Journal of pediatric gastroenterology and nutrition.

[52]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.

[53]  D. Cooper,et al.  Relationships Between Pulmonary Function and Plasma Fatty Acid Levels in Cystic Fibrosis Patients , 1986, Journal of pediatric gastroenterology and nutrition.

[54]  P. Kuo,et al.  The fatty acid composition of the serum chylomicrons and adipose tissue of children with cystic fibrosis of the pancreas. , 1962, The Journal of pediatrics.

[55]  A. Seegmiller,et al.  The effects of ivacaftor on CF fatty acid metabolism: An analysis from the GOAL study. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[56]  T. Rideout,et al.  Dietary oils and FADS1-FADS2 genetic variants modulate [13C]α-linolenic acid metabolism and plasma fatty acid composition. , 2013, The American journal of clinical nutrition.

[57]  N. Kalupahana,et al.  Health benefits of n-3 polyunsaturated fatty acids: eicosapentaenoic acid and docosahexaenoic acid. , 2012, Advances in food and nutrition research.

[58]  J. Zieleński,et al.  Prostaglandin-endoperoxide synthase genesCOX1 andCOX2 — novel modifiers of disease severity in cystic fibrosis patients , 2011, Journal of Applied Genetics.

[59]  C. Léger,et al.  Delta6- and delta5-desaturase activities in the human fetal liver: kinetic aspects. , 1998, Journal of lipid research.

[60]  J. Zieleński,et al.  Cystic fibrosis: genotypic and phenotypic variations. , 1995, Annual review of genetics.

[61]  W. Raynor,et al.  Correction of Linoleic Acid Deficiency in Cystic Fibrosis , 1986, Pediatric Research.